Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 4/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630551 | 0.94 | NAALAD2 (0.50) | QRFPRENPEPOPRD1OPRM1OPRK1 | |
| SCHEMBL30111298 | 0.94 | OPRD1 (0.48) | QRFPRENPEPOPRD1OPRM1OPRK1 | |
| SCHEMBL29591506 | 0.93 | NAALAD2 (0.48) | ENPEPNAALAD2NPY1RNPY2RNPY4R | |
| SCHEMBL29595894 | 0.90 | MME (0.46) | QRFPROPRD1OPRM1OPRK1 | |
| SCHEMBL31257035 | 0.89 | OPRD1 (0.52) | ENPEPOPRD1OPRM1OPRK1NPY1R | |
| SCHEMBL29630734 | 0.88 | NAALAD2 (0.54) | ENPEPNAALAD2NPY1RNPY2RNPY4R | |
| SCHEMBL29592666 | 0.87 | NPY5R (0.49) | OPRD1OPRM1OPRK1NPY1RNPY2R | |
| SCHEMBL29735690 | 0.87 | NAALAD2 (0.56) | ENPEPOPRD1OPRM1OPRK1NAALAD2 | |
| SCHEMBL29630542 | 0.86 | NAALAD2 (0.55) | ENPEPNAALAD2NPY1RNPY2RNPY4R | |
| SCHEMBL29707527 | 0.86 | NAALAD2 (0.55) | ENPEPNAALAD2NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | QRFPR 859/4885ENPEP 550/4885OPRD1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.